Regeneron Pharmaceuticals, Inc.
MX ˙ BMV ˙ US75886F1075
SecurityMX:REGN / Regeneron Pharmaceuticals, Inc.
InstitutionCardinal Capital Management
Latest Disclosed Ownership8,436 shares
Latest Disclosed Value $ 6,517,992
Cardinal Capital Management reports 0.36% increase in ownership of REGN / Regeneron Pharmaceuticals, Inc.

On April 8, 2026 - Cardinal Capital Management filed a 13F-HR form disclosing ownership of 8,436 shares of Regeneron Pharmaceuticals, Inc. (MX:REGN) valued at $6,517,992 USD as of March 31, 2026. The entity filed a previous 13F-HR on January 30, 2026 disclosing 8,406 shares of Regeneron Pharmaceuticals, Inc.. This represents a change in shares of 0.36% during the quarter.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-04-08 2026-03-31 13F REGENERON PHARMACEUTICALS COM 75886F107 8,436 30 0.36 6,518 0.45 0.8403
2026-01-30 2025-12-31 13F REGENERON PHARMACEUTICALS COMMON STOCK 75886F107 8,406 -25 -0.30 6,488 36.88 0.8594
2025-10-23 2025-09-30 13F REGENERON PHARMACEUTICALS Common Stock 75886F107 8,431 115 1.38 4,740 8.59 0.6553
2025-07-15 2025-06-30 13F REGENERON PHARMACEUTICALS Common Stock 75886F107 8,316 280 3.48 4,366 -14.34 0.6407
2025-04-18 2025-03-31 13F REGENERON PHARMACEUTICALS Common Stock 75886F107 8,036 165 2.10 5,097 -9.10 0.7893
2025-01-31 2024-12-31 13F REGENERON PHARMACEUTICALS Common Stock 75886F107 7,871 36 0.46 5,607 -31.93 0.8793
2024-10-16 2024-09-30 13F REGENERON PHARMACEUTICALS Common Stock 75886F107 7,835 45 0.58 8,236 0.60 1.2814
2024-07-12 2024-06-30 13F REGENERON PHARMACEUTICALS Common Stock 75886F107 7,790 16 0.21 8,188 9.42 1.3790
2024-07-12 2024-03-31 13F/A-1 REGENERON PHARMACEUTICALS Common Stock 75886F107 7,774 284 3.79 7,482 13.74 1.2175
2024-04-15 2024-03-31 13F REGENERON PHARMACEUTICALS Common Stock 75886F107 7,774 284 7,482 1.2175
2024-07-12 2023-12-31 13F/A-1 REGENERON PHARMACEUTICALS COM 75886F107 7,490 -16 -0.21 6,578 6.49 1.2457
2024-01-29 2023-12-31 13F REGENERON PHARMACEUTICALS COM 75886F107 7,490 -16 6,578 1.2457
2024-07-12 2023-09-30 13F/A-1 REGENERON PHARMACEUTICALS Common Stock 75886F107 7,506 88 1.19 6,177 15.89 1.2574
2023-10-16 2023-09-30 13F REGENERON PHARMACEUTICALS Common Stock 75886F107 7,506 88 6,177 1.2574
2024-07-12 2023-06-30 13F/A-1 REGENERON PHARMACEUTICALS Common Stock 75886F107 7,418 57 0.77 5,330 -11.87 1.0734
2023-07-12 2023-06-30 13F REGENERON PHARMACEUTICALS Common Stock 75886F107 7,418 57 5,330 1.0734
2023-04-19 2023-03-31 13F REGENERON PHARMACEUTICALS Common Stock 75886F107 7,361 -55 -0.74 6,048 13.05 1.2549
2023-01-23 2022-12-31 13F REGENERON PHARMACEUTICALS COM 75886F107 7,416 -46 -0.62 5,351 4.09 1.1389
2022-10-24 2022-09-30 13F REGENERON PHARMACEUTICALS Common Stock 75886F107 7,462 68 0.92 5,140 17.59 1.2165
2022-08-04 2022-06-30 13F REGENERON PHARMACEUTICALS Common Stock 75886F107 7,394 30 0.41 4,371 -15.01 1.0002
2022-04-21 2022-03-31 13F REGENERON PHARMACEUTICALS Common Stock 75886F107 7,364 130 1.80 5,143 12.59 1.0404
2022-01-18 2021-12-31 13F REGENERON PHARMACEUTICALS Common Stock 75886F107 7,234 -22 -0.30 4,568 4.03 0.9046
2021-10-21 2021-09-30 13F REGENERON PHARMACEUTICALS Common Stock 75886F107 7,256 -83 -1.13 4,391 7.12 0.9507
2021-07-14 2021-06-30 13F REGENERON PHARMACEUTICALS Common Stock 75886F107 7,339 -25 -0.34 4,099 17.65 0.8654
2021-04-19 2021-03-31 13F REGENERON PHARMACEUTICALS Common Stock 75886F107 7,364 96 1.32 3,484 -0.77 0.7682
2021-02-01 2020-12-31 13F REGENERON PHARMACEUTICALS Common Stock 75886F107 7,268 66 0.92 3,511 -12.92 0.8313
2020-10-16 2020-09-30 13F REGENERON PHARMACEUTICALS Common Stock 75886F107 7,202 -7 -0.10 4,032 -10.30 1.1109
2020-07-16 2020-06-30 13F REGENERON PHARMACEUTICALS Common Stock 75886F107 7,209 -29 -0.40 4,495 27.19 1.2933
2020-04-20 2020-03-31 13F Regeneron Pharmaceuticals Common Stock 75886F107 7,238 299 4.31 3,534 35.66 1.1672
2020-01-21 2019-12-31 13F REGENERON PHARMACEUTICALS Common Stock 75886F107 6,939 6,939 2,605 0.6764
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.